Backgroud: The introduction of highly active immunotherapies has changed the outcome of B-cell non-Hodgkin lymphomas (B-NHLs) in the last two decades. Since then, important progress has been shown using newer and more active immunotherapies, including chimeric antigen receptor T-cell therapy (CAR-T), conjugated monoclonal antibodies, and bispecific antobodies, which currently plays a significant role in the treatment of diffuse large B-cell (DLBCL), follicular (FL), and mantle cell (MCL) lymphoma. Purpose: In this review, we provide an updated overview of recently completed and ongoing BsAb trials in patients with relapsed/refractory(R/R) B-NHL and Hodgkin’s lymphoma, including single-agent results, emerging combinations, safety data, and novel constructs. Conclusions: Bispecific antibodies (BsAbs) are a novel class of “off-the-shelf” T-cell-redirecting drugs capable of targeting various cell-surface antigens. New antigen targets are currently under investigation, such as CD19 × CD3 and CD30 × CD3 or CD30 × CD16, in different settings. BsAbs are among the most promising therapeutic options for lymphoma today since they have demonstrated significant single-agent activity, along with a manageable toxicity profile, in patients with heavily pretreated B-NHL.
背景：过去二十年间，高活性免疫疗法的引入改变了B细胞非霍奇金淋巴瘤（B-NHLs）的治疗格局。此后，以嵌合抗原受体T细胞疗法（CAR-T）、偶联单克隆抗体和双特异性抗体为代表的新型高效免疫疗法取得重要进展，目前在弥漫性大B细胞淋巴瘤（DLBCL）、滤泡性淋巴瘤（FL）和套细胞淋巴瘤（MCL）治疗中发挥着重要作用。目的：本文综述了复发/难治性（R/R）B细胞非霍奇金淋巴瘤及霍奇金淋巴瘤患者中已完成及正在进行的双特异性抗体临床试验最新进展，涵盖单药疗效、新兴联合疗法、安全性数据及新型结构设计。结论：双特异性抗体（BsAbs）是一类新型"即用型"T细胞重定向药物，能够靶向多种细胞表面抗原。目前针对不同靶点组合（如CD19×CD3、CD30×CD3或CD30×CD16）的新型抗原靶标正在研究中。对于经过多线治疗的B细胞非霍奇金淋巴瘤患者，双特异性抗体已展现出显著的单药活性及可控的毒性特征，使其成为当前淋巴瘤治疗领域最具前景的治疗选择之一。
肿瘤(癌症)患者之家